LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study

Fabrice Barlési, Laurent Greillier, F. Monville, Cyril Foa, J. Le Treut, Clarisse Audigier-Valette, Frédéric Vely, Samuel García, Florence Sabatier, Joseph Ciccolini, Myriam Fabre, Maryannick Le Ray, Noémie Resseguier, Pernelle Outters, Marie Roumieux, Julien Mazières, M. Pérol, Éric Vivier, Pascal Auquier, Jacques Fieschi